A postdoctoral fellow position is available in the Laboratory of Dr. Naoto Hirano in the Tumor Immunotherapy Program at the Princess Margaret Cancer Center. The fellow will be engaged in the development of novel immunotherapeutics for cancer. Find below some of the recent works published from the Hirano laboratory.
1. Kagoya et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018
2. Yamashita et al. HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nat Commun. 2016
3. Kagoya et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016
4. Ochi et al. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunol Res. 2015
5. Butler and Hirano. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev. 2014
Candidates should have a background in cancer immunology and immunotherapy with experience in biochemistry and molecular biology.
PhD or MD degree awarded recently.
Candidates must be highly motivated, possess excellent communication skills and a strong record of scientific accomplishments, including publications in peer-reviewed journals and scientific presentations.
Applicants should respond by email with a curriculum vitae, brief description of research interests, and contact information of three referees in one PDF document to Dr. Naoto Hirano (email@example.com)
Naoto Hirano, MD, PhD